MT
Marrow Therapeutics
United States · Biotech · Healthtech
Marrow Therapeutics develops bone marrow-targeted genetic medicines for severe blood disorders.
Product
Marrow aims to treat sickle cell disease, beta thalassemia and other blood disorders by delivering therapeutic payloads directly to bone marrow cells. Its Transferrin Antibody Bioconjugate platform uses engineered antibodies to target the transferrin receptor. Lead candidate MAR-101 is in studies preparing for an investigational clinical-trial application.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $120M | OrbiMed — LeadAffinity Advisors — ParticipantColumbia Threadneedle Investments — ParticipantKKR — ParticipantNEXTBio Capital — ParticipantOpaleye — ParticipantRTW Investments — ParticipantScion Life Sciences — ParticipantSpruce Street Capital — ParticipantSurveyor Capital — ParticipantvenBio — Participant | |
| Series A financing disclosure | $53M | Scion Life Sciences — LeadvenBio — Lead |